ASX:PAR

Paradigm Biopharmaceuticals Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume1.81 million shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive PAR News and Ratings via Email

Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Paradigm Biopharmaceuticals has study supporting arthritic disease modifying effects of PPS in chikungunya virus published in peer-reviewed journal
September 13, 2021 | proactiveinvestors.com.au

‘Who Killed Sara?’ Star Carolina Miranda Signs With Paradigm
September 8, 2021 | msn.com

Paya, Paradigm Construct Payments Solution for the Building Industry
September 7, 2021 | pymnts.com

Rhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare Conference
September 2, 2021 | finance.yahoo.com

HDT Bio Partners with Brazil’s SENAI CIMATEC to Advance RNA COVID-19 Vaccine to Fight Pandemic
August 31, 2021 | nz.finance.yahoo.com

Paradigm Biopharmaceuticals prepares for “pivotal” phase three clinical trial over FY21
August 27, 2021 | proactiveinvestors.com.au

EpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for the treatment of COPD
August 19, 2021 | businesswire.com

Paradigm Biopharmaceuticals' pre-clinical food study in chronic heart failure continues ahead of commentary in Q4
August 10, 2021 | proactiveinvestors.com.au

Biopharmaceutical Contract Manufacturing Market, 2030 - ResearchAndMarkets.com
August 10, 2021 | finance.yahoo.com

Pacquiao vs Spence: Paradigm injunction request tentatively denied
August 7, 2021 | msn.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolASX:PAR
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.paradigmbiopharma.com
Phone61 3 9629 5566
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$20,550.00
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow6.44
Book ValueA$0.34 per share
Price / BookN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Paradigm Biopharmaceuticals.

5.0 Community Rank

Outperform Votes
Paradigm Biopharmaceuticals has received 32 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Paradigm Biopharmaceuticals has received 10 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Paradigm Biopharmaceuticals has received 76.19% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Paradigm Biopharmaceuticals and other stocks. Vote “Outperform” if you believe PAR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PAR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Paradigm Biopharmaceuticals does not currently pay a dividend.
Dividend Growth
Paradigm Biopharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Paradigm Biopharmaceuticals insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Paradigm Biopharmaceuticals (ASX:PAR) Frequently Asked Questions

What stocks does MarketBeat like better than Paradigm Biopharmaceuticals?

Wall Street analysts have given Paradigm Biopharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Paradigm Biopharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Paradigm Biopharmaceuticals' key executives?

Paradigm Biopharmaceuticals' management team includes the following people:

Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC, CEO, MD & Exec. Chairman (Age 62, Pay $632.36k)
Mr. Justin Cahill, Chief Financial Officer
Dr. Jeannette Joughin, Chief Operating Officer
Dr. Ravi Krishnan, Chief Scientific Officer
Ms. Simon White, Director of Investor Relations
Dr. Michael Imperiale, Global Head of Safety
Dr. Donna L. Skerrett, Chief Medical Officer & Exec. Director (Age 64)
Ms. Beverley Huttmann, Commercial Head
Ms. Michelle Coffey, Global Head of Regulatory Affairs
Mr. Kevin G. Hollingsworth, Company Sec. (Age 68)

Who are some of Paradigm Biopharmaceuticals' key competitors?

Some companies that are related to Paradigm Biopharmaceuticals include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR) and Annovis Bio (ANVS).
View all of PAR's competitors.

What other stocks do shareholders of Paradigm Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), First Graphene (FGR), Envirosuite (EVS), Bubs Australia (BUB), Blue Energy (BLU), BHP Group (BHP), Alcidion Group (ALC), The a2 Milk (A2M) and 8common (8CO).

What is Paradigm Biopharmaceuticals' stock symbol?

Paradigm Biopharmaceuticals trades on the ASX under the ticker symbol "PAR."

How much money does Paradigm Biopharmaceuticals make?

Paradigm Biopharmaceuticals has a market capitalization of $0.00 and generates $20,550.00 in revenue each year.

How many employees does Paradigm Biopharmaceuticals have?

Paradigm Biopharmaceuticals employs 1,031 workers across the globe.

What is Paradigm Biopharmaceuticals' official website?

The official website for Paradigm Biopharmaceuticals is www.paradigmbiopharma.com.

Where are Paradigm Biopharmaceuticals' headquarters?

Paradigm Biopharmaceuticals is headquartered at Par Technology Park, New Hartford, New York 13413.

How can I contact Paradigm Biopharmaceuticals?

Paradigm Biopharmaceuticals' mailing address is Par Technology Park, New Hartford, New York 13413. The company can be reached via phone at 61 3 9629 5566.

This page was last updated on 9/19/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Paradigm Biopharmaceuticals Stock Forecast, Price & News

About Paradigm Biopharmaceuticals

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

5.0 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment